BioSpace News Archive

Elevation Oncology, Inc. today announced financial results for the second quarter ended June 30, 2023, and highlighted recent business achievements.

Sonoma Pharmaceuticals, Inc. today announced the appointment of Dr. Hye Jin Chung MD, MMSc, Assistant Professor of Dermatology at Harvard Medical School in Boston and practicing dermatologist at Beth Israel Deaconess Medical Center, to the company’s Scientific Advisory Board.

Immunocore Holdings Plc announced that it will report second quarter financial results, before the US markets open on Thursday, August 10, 2023.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced three recent publications highlighting its Deep Transcranial Magnetic Stimulation in leading peer-reviewed medical journals.

Daré Bioscience, Inc., a leader in women’s health innovation, announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results for the quarter ended June 30, 2023 and to provide a Company update.

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Biora Therapeutics, Inc. (Nasdaq: BIOR) today announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.

Addex Therapeutics announced that its collaboration agreement with Indivior PLC for the discovery of novel oral gamma-aminobutyric acid subtype B positive allosteric modulator drug candidates for the treatment of substance use disorder has been extended until June 30, 2024.

LIfT BioSciences reports a substantially marked increase in cancer killing with the attachment of HER2 CAR to its IMAN cell therapy, using the Company’s second-generation N-LIfT platform.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2023, and provides a corporate update.